Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DaVita (DE:TRL)
FRANKFURT:TRL
DaVita (TRL) Stock Price & Analysis
2 Followers
TRL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€69.24 - €138.75
Previous Close€128.65
Volume0.00
Average Volume (3M)66.00
Market Cap
€11.40B
Enterprise Value€22.80B
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$11.12B
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Aug 01, 2024EPS Estimate
€2.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding87,700,000
10 Day Avg. Volume7
30 Day Avg. Volume66
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.98
Price to Sales (P/S)0.94
Price to Cash Flow (P/CF)6.40
P/FCF Ratio8.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda10.77
Forecast
1Y Price Target
€132.69Price Target Upside3.34% Upside
Rating ConsensusHold
Number of Analyst Covering4
DaVita News
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PerformanceDVA raised the adj OI guidance by $50m at the low end as pricing in the quarter came in better vs internal expectations.
Operational EfficiencyImproving capacity utilization is a large lever to better margins, and DVA has closed or consolidated sites to improve margins.
Study ResultsThe study found that patients in the semaglutide group had CKD progression slowed by about 27% compared to the placebo group.
Bears Say
Drug EfficacyFor patients already taking SGLT2 inhibitors, the study found no statistically significant benefit in the experimental group.
Regional PerformanceNorth America saw only a 2% benefit versus the placebo group, whereas Europe (39%) and Other geographies recorded significantly higher benefits that drove headline results.
Sales VolumeSame store vols were +0.4% y/y, decelerating from +0.7% y/y in 4Q23, despite the extra day from leap year.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.11% Other Institutional Investors
99.89% Public Companies and
Individual Investors
TRL FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was €69.24 and its highest was €138.75 in the past 12 months.
What is DaVita’s market cap?
Currently, no data Available
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Aug 01, 2024 which is in 5 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on May 02, 2024. The company reported €2.185 earnings per share for the quarter, beating the consensus estimate of €1.788 by €0.397.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is €2.38.
How many shares outstanding does DaVita have?
Currently, no data Available
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of €2.185 in its last earnings report, beating expectations of €1.788. Following the earnings report the stock price went down -4.776%.
Which hedge fund is a major shareholder of DaVita?
Among the largest hedge funds holding DaVita’s share is Berkshire Hathaway Inc. It holds DaVita’s shares valued at 5B.
---
DaVita Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€132.69 (3.34% Upside)
€132.69 (3.34% Upside)
Blogger Sentiment
Bullish
DE:TRL Sentiment 87%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $698.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.77%
12-Months-Change
Fundamentals
Return on Equity
93.14%
Trailing 12-Months
Asset Growth
4.20%
Trailing 12-Months
Company Description
DaVita
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
---
TRL Earnings Call
Q1 2024
0:00 / 0:00
---
TRL Revenue Breakdown
95.34% U.S. dialysis
4.66% Ancillary services
---
TRL Stock 12 Month Forecast
Average Price Target
€132.69
▲(3.34% Upside)
Technical Analysis
Best Analysts Covering TRL
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-36.52%
reiterated a sell rating 2 months ago
Copying Kevin Fischbeck's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.52% per trade.
---